Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial
Monthly and quarterly administered fremanezumab effectively prevented EM in Japanese and Korean patients. Fremanezumab also improved other disease aspects including the need for acute headache medications and the frequency of migraine-associated symptoms.
Authors
- Byungkun Kim
- C OSAWA (ORCID: https://orcid.org/0009-0009-4241-781X)
- Katsuhiro Iba (ORCID: https://orcid.org/0000-0003-1521-9067)
- Masami Nakai (ORCID: https://orcid.org/0000-0001-5159-0432)
- Muneto Tatsumoto (ORCID: https://orcid.org/0000-0002-1950-0756)
- Yuka Kurita
- Miki Ishida (ORCID: https://orcid.org/0000-0001-8723-2717)
- Xiaoping Ning
Institutions
- Otsuka (Japan) (JP)
- Canon (Japan) (JP)
- Eulji University (KR)
- Teva Pharmaceuticals (United States) (US)
- Dokkyo Medical University (JP)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1111/head.14810
- Citations
- 1
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.39